Now trading at a price of $46.05, Hims & Hers Health has moved -2.3% so far today.
Hims & Hers Health returned gains of 202.5% last year, with its stock price reaching a high of $72.98 and a low of $13.47. Over the same period, the stock outperformed the S&P 500 index by 186.0%. More recently, the company's 50-day average price was $53.13. Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. Based in San Francisco, CA, the Large-Cap Health Care company has 1,637 full time employees. Hims & Hers Health has not offered a dividend during the last year.
Wider Gross Margins Than the Industry Average of 44.08%:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $82,558 | $148,757 | $271,878 | $526,916 | $872,000 | $1,476,514 |
| Gross Margins | 54% | 74% | 75% | 78% | 82% | 79% |
| Net Margins | -87% | -12% | -40% | -12% | -3% | 9% |
| Net Income (k) | -$72,064 | -$18,114 | -$107,659 | -$65,678 | -$23,546 | $126,038 |
| Net Interest Expense (k) | $369 | -$2,843 | n/a | $2,988 | $7,882 | $9,808 |
| Depreciation & Amort. (k) | $260 | $1,057 | $4,075 | $7,474 | $9,515 | $17,088 |
| Diluted Shares (k) | 34,759 | 35,354 | 186,782 | 204,516 | 209,345 | 236,809 |
| Earnings Per Share | -$2.07 | -$0.51 | -$0.58 | -$0.32 | -$0.11 | $0.53 |
| EPS Growth | n/a | 75.36% | -13.73% | 44.83% | 65.62% | 581.82% |
| Avg. Price | $9.87 | $10.42 | $11.02 | $4.63 | $8.9 | $47.13 |
| P/E Ratio | -4.77 | -20.43 | -19.0 | -14.47 | -80.91 | 81.26 |
| Free Cash Flow (k) | -$75,175 | -$4,216 | -$35,244 | -$29,245 | $56,263 | $212,284 |
| CAPEX (k) | $308 | $1,737 | $832 | $2,714 | $17,220 | $38,800 |
| Current Ratio | 3.38 | 7.43 | 3.41 | 4.52 | 3.0 | 1.79 |
Hims & Hers Health benefits from rapidly growing revenues and increasing reinvestment in the business, wider gross margins than its peer group, and positive EPS growth. The company's financial statements show positive cash flows and a decent current ratio of 1.79.
The Market May Be Overvaluing Hims & Hers Health's Earnings and Assets:
Hims & Hers Health has a trailing twelve month P/E ratio of 67.3, compared to an average of 22.94 for the Health Care sector. Based on its EPS guidance of $0.46, the company has a forward P/E ratio of 115.5. The 2.9% compound average growth rate of Hims & Hers Health's historical and projected earnings per share yields a PEG ratio of 23.12. This suggests that these shares are overvalued. Furthermore, Hims & Hers Health is likely overvalued compared to the book value of its equity, since its P/B ratio of 18.48 is higher than the sector average of 3.19. The company's shares are currently trading 839.7% below their Graham number. Overall, Hims & Hers Health's lofty valuation in terms of earnings and assets is to some extent attenuated by its strong cash flow trend and reasonable levels of debt.
Hims & Hers Health Has an Average Rating of Hold:
The 11 analysts following Hims & Hers Health have set target prices ranging from $28.0 to $85.0 per share, for an average of $50.45 with a hold rating. The company is trading -8.7% away from its average target price, indicating that there is an analyst consensus of some upside potential.
Hims & Hers Health has an unusually large proportion of its shares sold short because 35.5% of the company's shares are sold short. Institutions own 88.0% of the company's shares, and the insider ownership rate stands at 10.63%, suggesting a large amount of insider shareholders. The largest shareholder is Blackrock Inc., whose 11% stake in the company is worth $1,139,584,880.
